發(fā)布時間：2018-08-20 12:58

【摘要】：目的:觀察血必凈注射液聯(lián)合亞胺培南西司他丁治療腹腔重癥感染的臨床療效、安全性及對患者血漿內毒素、炎癥因子的影響。方法:選取2013年4月-2016年4月在我院接受治療的腹腔重癥感染患者100例,按隨機數(shù)字表法分為觀察組和對照組,各50例。對照組患者給予注射用亞胺培南西司他丁鈉0.5 g加入0.9%氯化鈉注射液500 m L中,ivgtt(時間≥40 min),q12 h;觀察組患者在對照組基礎上間隔8 h給予血必凈注射液100 m L加入0.9%氯化鈉注射液500 m L中,ivgtt,bid。兩組患者均治療5~7d。比較兩組患者治療前后血漿內毒素和炎癥因子[腫瘤壞死因子α(TNF-α)、白細胞介素6(IL-6)、IL-6/IL-10]水平及臨床療效,并記錄不良反應發(fā)生情況。結果:治療前,兩組患者血漿內毒素和炎癥因子水平比較,差異均無統(tǒng)計學意義(P0.05);治療后,兩組患者血漿內毒素和炎癥因子水平均顯著下降,且觀察組水平顯著低于對照組,差異均有統(tǒng)計學意義(P0.05)。觀察組患者優(yōu)良率為98.00%,顯著高于對照組的78.00%,差異有統(tǒng)計學意義(P0.05)。兩組患者均未見明顯不良反應發(fā)生。結論:血必凈注射液聯(lián)合亞胺培南西司他丁治療腹腔重癥感染療效顯著,能有效控制患者內毒素以及炎癥因子的釋放,且安全性較高。
[Abstract]:OBJECTIVE: To observe the clinical efficacy and safety of Xuebijing injection combined with imipenem cilastatin in the treatment of severe abdominal infections and its effect on plasma endotoxin and inflammatory factors.Methods: 100 patients with severe abdominal infections who were treated in our hospital from April 2013 to April 2016 were divided into observation group and control group according to random number table method. The control group was given imipenem cilastatin sodium 0.5 g for injection into 0.9% sodium chloride injection 500 m L, IVGTT (time < 40 min), Q12 h; the observation group was given Xuebijing injection 100 m L added to 0.9% sodium chloride injection 500 m L, ivgtt, bid. The levels of plasma endotoxin and inflammatory factors [tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-6 (IL-6), and IL-10] were measured before and after treatment, and the adverse reactions were recorded. The levels of plasma endotoxin and inflammatory factors in the observation group were significantly lower than those in the control group, and the difference was statistically significant (P 0.05). The excellent and good rate of the observation group was 98.00%, which was significantly higher than that of the control group (78.00%). The difference was statistically significant (P 0.05). The combination of imipenem and cilastatin is effective in the treatment of severe abdominal infections and can effectively control the release of endotoxin and inflammatory factors.
【作者單位】： 齊齊哈爾醫(yī)學院附屬第三醫(yī)院檢驗科;齊齊哈爾醫(yī)學院附屬第三醫(yī)院腫瘤一科;
【分類號】：R51

【相似文獻】

相關期刊論文 前8條

1 楊興易;重癥感染的幾個基本問題[J];中華急診醫(yī)學雜志;2004年02期

2 ;第三屆重癥感染高峰論壇[J];繼續(xù)醫(yī)學教育;2007年27期

3 溫小鳳;;人豬鏈球菌重癥感染2例[J];華西醫(yī)學;2007年01期

4 高燕;;鼎力攜手 再創(chuàng)輝煌——第六屆重癥感染高峰論壇會議紀要[J];中國實用內科雜志;2009年06期

5 喬富渠;;G組鏈球菌所致嚴重感染(15例報告)[J];右江醫(yī)學;1985年02期

6 羅繼征;郝從軍;孟軍英;;重癥感染并發(fā)中心靜脈導管相關性感染的診治探討[J];華北國防醫(yī)藥;2006年06期

7 劉文娟;周冰;;人豬鏈球菌Ⅱ型重癥感染2例[J];臨床薈萃;2009年13期

8 李志強;邱方;王瑞剛;程愛斌;;持續(xù)輸注β-內酰氨類抗生素方案治療重癥感染患者的系統(tǒng)評價[J];中國醫(yī)院藥學雜志;2009年06期

，

本文編號：2193684